Not a healthcare professional? Visit our Public site
For UK Healthcare Professionals
This site may contain promotional material
Report adverse event
User logged in
fluticasone furoate/vilanterol inhalation powder
Summary of product characteristics
Patient information leaflet
Incruse▼ Ellipta (umeclidinium bromide inhalation powder) prescribing information
This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.
Request a contact
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
Relvar, Incruse and Ellipta are registered trademarks of the GlaxoSmithKline group of companies
V.T. Last updated: July 2017 UK/FFT/0232/15(5)
Get in touch
To discuss our products, supply, educational events or any other information
© 2009-2017 GSK group of companies. All rights reserved. GlaxoSmithKline UK Limited Registered in England and Wales No 4310159.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.
M.C. Last updated: April 2017. UK/COM/0106/15(1).
This browser is not supported and will result in the website not being optimally presented. You are recommended to use an alternate browser such as Chrome, Opera or FireFox